

117TH CONGRESS  
1ST SESSION

# H. R. 1185

To amend the Public Health Service Act to authorize grants to certain States to inform patients about the risks of opioids and their analogues, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 18, 2021

Mr. TRONE (for himself, Mr. RESCHENTHALER, Ms. LEGER FERNANDEZ, and Mr. MCKINLEY) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to authorize grants to certain States to inform patients about the risks of opioids and their analogues, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Opioid Patients’ Right  
5       to Know Act of 2021”.

1 **SEC. 2. GRANT PROGRAM TO INFORM PATIENTS ABOUT**  
2 **THE RISKS OF OPIOIDS AND THEIR ANA-**  
3 **LOGUES.**

4 Part J of title III of the Public Health Service Act  
5 (42 U.S.C. 280b et seq.) is amended by inserting after  
6 section 392A (42 U.S.C. 280b–1) the following:

7 **“SEC. 392B. GRANT PROGRAM TO INFORM PATIENTS ABOUT**  
8 **THE RISKS OF OPIOIDS AND THEIR ANA-**  
9 **LOGUES.**

10 “(a) IN GENERAL.—The Secretary, acting through  
11 the Director of the Centers for Disease Control and Pre-  
12 vention, shall award one grant (over the life of the pro-  
13 gram under this section) to each eligible State to inform  
14 covered health care providers about—

15 “(1) the requirement of the State described in  
16 subsection (b); and

17 “(2) recommendations for safe opioid pre-  
18 scribing.

19 “(b) ELIGIBILITY.—To be eligible to receive a grant  
20 under subsection (a), a State must have in effect a law  
21 or regulation requiring covered health care providers, be-  
22 fore issuing a new prescription for a covered drug or ana-  
23 logue, to inform the patient involved, and the patient’s  
24 guardian if the patient has a guardian, about—

25 “(1) the risks of such covered drug or analogue;

1           “(2) the addictive qualities of such covered drug  
2           or analogue; and

3           “(3) non-opioid treatments to such covered  
4           drug or analogue, as appropriate.

5           “(c) GRANT AMOUNT.—The amount of a grant to a  
6           State under this section—

7           “(1) shall be greater than the amount of each  
8           grant to a State with a smaller number of covered  
9           health providers, as estimated by the Secretary;

10          “(2) shall not exceed \$1,000,000; and

11          “(3) subject to the availability of funds, shall  
12          not be less than \$750,000.

13          “(d) DEFINITIONS.—For purposes of this section:

14          “(1) COVERED DRUG OR ANALOGUE.—The  
15          term ‘covered drug or analogue’ means a drug that  
16          is or contains an opioid (as defined in section 102  
17          of the Controlled Substances Act) or an analogue of  
18          an opioid.

19          “(2) COVERED HEALTH CARE PROVIDER.—The  
20          term ‘covered health care provider’ means a health  
21          care provider who issues prescriptions for a covered  
22          drug or analogue for the relief of acute pain.

1       “(e) AUTHORIZATION OF APPROPRIATIONS.—There  
2 is authorized to be appropriated to carry out this section  
3 \$10,000,000 for each of fiscal years 2022 through 2031.”.

○